Rituximab and short‐course prednisone as the new gold standard for new‐onset pemphigus vulgaris and pemphigus foliaceus-Reference-Cited by-同舟云学术

Rituximab and short‐course prednisone as the new gold standard for new‐onset pemphigus vulgaris and pemphigus foliaceus

Published:2017-11 Issue:5 Volume:177 Page:1143-1144
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Murrell D.F.¹^ORCID,Sprecher E.²

Affiliation:

1. Department of Dermatology St George Hospital University of New South Wales Sydney NSW Australia

2. Tel Aviv Medical Centre Tel Aviv Israel

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.15947

Reference13 articles.

1. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

2. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

3. Interventions for pemphigus vulgaris and pemphigus foliaceus;Martin LK;Cochrane Database Syst Rev,2009

4. FDA News.FDA grants breakthrough therapy designation for rituxan in pemphigus vulgaris. Available at:http://www.fdanews.com/articles/181113-fda-grants-breakthrough-therapy-designation-for-rituxan-in-pemphigus-vulgaris(last accessed 29 August 2017).

5. Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Global View of Pemphigus: Geographical Variations;Clinical Reviews in Allergy & Immunology;2024-01-30

2. Off-Label Uses of Rituximab in Dermatology;Current Dermatology Reports;2022-10-06

3. Pemphigus for the Inpatient Dermatologist;Current Dermatology Reports;2022-09-02

4. Verrucous Scalp Plaque and Widespread Eruption;Cutis;2021-08-01

5. De-escalation of anti-CD20 monoclonal antibody (Rituximab) protocols in Pemphigus Vulgaris – a systematic review;Expert Opinion on Biological Therapy;2021-06-11